• Publications
  • Influence
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT)
CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has not beenExpand
  • 2,251
  • 69
  • Open Access
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Oral daily (2.5 mg) and intermittent ibandronate (between‐dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebralExpand
  • 1,054
  • 53
  • Open Access
Bone mineral content of amenorrheic and eumenorrheic athletes.
This study was designed to determine whether the hypoestrogenic status of 14 amenorrheic athletes was associated with a decrease in regional bone mass relative to that of 14 of their eumenorrheicExpand
  • 873
  • 22
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Abstract Background. To determine the effects of etidronate (a bisphosphonate that inhibits osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we conducted aExpand
  • 804
  • 20
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Less frequent bisphosphonate dosing in women with postmenopausal osteoporosis has the potential to promote therapy adherence through improved convenience. Ibandronate is a highly potentExpand
  • 145
  • 18
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
PURPOSE We conducted a 5-year, double-blind, randomized, placebo-controlled study to determine whether salmon calcitonin nasal spray reduced the risk of new vertebral fractures in postmenopausalExpand
  • 966
  • 17
  • Open Access
Fractures Attributable to Osteoporosis: Report from the National Osteoporosis Foundation
To assess the cost‐effectiveness of interventions to prevent osteoporosis, it is necessary to estimate total health care expenditures for the treatment of osteoporotic fractures. Resources utilizedExpand
  • 498
  • 17
Menstrual history as a determinant of current bone density in young athletes.
The relationship of prior menstrual irregularities and current menstrual status to the bone density of 97 young athletes was determined at seven sites using single- and dual-photon absorptiometry.Expand
  • 361
  • 17
Denosumab in postmenopausal women with low bone mineral density.
BACKGROUND Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerlyExpand
  • 369
  • 15
  • Open Access
Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females.
We suggested that calcium may be an important determinant of peak bone mass. For further elucidation, calcium balances in adolescent females with different calcium intakes (270-1637 mg/d), and a 2-yExpand
  • 450
  • 11
  • Open Access